V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 10004957 | 10003102 | 1.68 | 77.7 | Curative (C) | 2016-10-25 | 2016-10-30 | Mitomycin Intravesical | 02 | N | 10555767 | MELPHALAN |
| 10004958 | 10003103 | 0 | 112 | Unknown (U) | 2017-02-27 | 2017-02-27 | Sorafenib | 2 | N | 10555795 | BORTEZOMIB + THALIDOMIDE |
| 10004959 | 10003104 | 1.68 | 77.3 | Palliative (P) | 2015-08-31 | 2015-10-02 | CISPLATIN + FLUOROURACIL + RT | N | N | 10555960 | SUNITINIB |
| 10004960 | 10003105 | 1.66 | 84.7 | Curative (C) | 2018-04-26 | 2018-05-02 | CETUXIMAB | 01 | N | 10555988 | CETUXIMAB + IRINOTECAN + MDG |
| 10004961 | 10003105 | 1.59 | 98.3 | null | 2014-01-05 | 2014-01-13 | Erlotinib | 02 | N | 10555988 | IDELALISIB + RITUXIMAB |
| 10004962 | 10003106 | 1.73 | 106 | Curative (C) | 2018-10-21 | 2018-10-25 | Cytarabine Low Dose | N | N | 10556056 | CHLORAMBUCIL + OBINUTUZUMAB |
| 10004963 | 10003107 | 0 | 70 | Neo-adjuvant (N) | 2016-09-11 | 2016-10-19 | IBRUTINIB | N | Y | 10556074 | MPV |
| 10004964 | 10003108 | 1.58 | 77.6 | Palliative (P) | null | 2017-06-19 | CYTARABINE + DAUNORUBICIN | 2 | N | 10556119 | VEMURAFENIB |
| 10004965 | 10003108 | 0 | 0 | Disease modification (D) | 2016-06-26 | 2016-06-27 | Etoposide oral | N | N | 10556119 | LENALIDOMIDE |
| 10004966 | 10003108 | 1.75 | null | Palliative (P) | 2017-10-19 | 2017-10-24 | Sorafenib | 2 | N | 10556119 | EOF |
| 10004967 | 10003109 | 1.68 | 0 | Palliative (P) | 2017-03-13 | 2017-03-14 | MPV (cycle 1-4) | Y | N | 10556277 | BENDAMUSTINE |
| 10004968 | 10003110 | null | 124.2 | Palliative (P) | 2017-09-04 | 2017-09-05 | Pazopanib | 99 | null | 10556411 | PCV |
| 10004969 | 10006762 | 1.85 | 82.8 | Palliative (P) | 2018-03-10 | 2018-03-14 | BLEOMYCIN | 2 | N | 10556434 | HCX |
| 10004970 | 10006762 | 1.65 | 54.1 | Disease modification (D) | 2018-08-07 | 2018-08-28 | Docetaxel+Gemcitabine (no prior RT) | 02 | N | 10556434 | PALBOCICLIB |
| 10004971 | 10006762 | 1.75 | 91.4 | Neo-adjuvant (N) | 2018-08-20 | 2018-08-27 | Cytarabine Low Dose | 02 | N | 10556434 | CARBOPLATIN + DOCETAXEL |
| 10004972 | 10003111 | 1.7 | null | Curative (C) | 2016-05-26 | 2016-05-26 | CETUXIMAB | 2 | N | 10556484 | CARBOPLATIN + DOCETAXEL |
| 10004973 | 10006763 | 1.69 | 0 | null | 2014-07-30 | 2014-08-03 | LEAM | N | N | 10556567 | ETOPOSIDE |
| 10004974 | 10003112 | 1.61 | 91.2 | Palliative (P) | 2015-04-13 | 2015-04-13 | AML18 PILOT TRIAL | Y | N | 10556575 | SORAFENIB |
| 10004975 | 10006764 | 1.56 | 77.6 | Curative (C) | 2016-01-17 | 2016-01-24 | Capecitabine (21days) + Carboplatin | N | N | 10556710 | NEPTUNE TRIAL |
| 10004976 | 10003113 | 0 | 66.9 | null | 2016-05-04 | 2016-06-02 | PATHOS Trial | 2 | N | 10556755 | CRIZOTINIB |
| 10004977 | 10003113 | 1.75 | 47 | Palliative (P) | 2018-11-13 | 2018-11-30 | DABRAFENIB + TRAMETINIB | N | N | 10556755 | DA |
| 10004978 | 10003113 | 1.68 | 85.4 | null | 2017-05-15 | 2017-06-10 | GEMCITABINE + NAB PACLITAXEL | 2 | N | 10556755 | CVP R + GEMCITABINE |
| 10004979 | 10003114 | 1.6 | 55 | Adjuvant (A) | 2017-02-21 | 2017-03-07 | CHLORAMBUCIL + OBINUTUZUMAB | N | N | 10556922 | IBRUTINIB |
| 10004980 | 10003115 | 1.7 | 75.8 | Disease modification (D) | 2015-05-27 | 2015-06-10 | Capecitabine (14 day) + Irinotecan | 01 | N | 10557035 | SUNITINIB |
| 10004981 | 10003115 | null | 55.6 | Palliative (P) | 2013-11-13 | 2013-11-23 | COMPLEMENT TRIAL | N | N | 10557035 | BLEOMYCIN |
| 10004982 | 10003116 | 1.7 | 78.6 | Curative (C) | 2018-04-19 | 2018-04-29 | Erlotinib | 2 | N | 10557484 | AFATINIB |
| 10004983 | 10003116 | 1.76 | 78 | Palliative (P) | 2013-08-03 | 2013-08-07 | DA | 2 | N | 10557484 | TEMOZOLOMIDE |
| 10004984 | 10003116 | 1.65 | 0 | Palliative (P) | 2019-06-22 | 2019-06-22 | Doxorubicin chemoembolisation | N | N | 10557484 | LOMUSTINE + PROCARBAZINE + VINCRISTINE |
| 10004985 | 10003116 | 1.63 | 54.6 | Palliative (P) | 2017-10-23 | 2017-10-23 | Docetaxel+Gemcitabine (no prior RT) | N | N | 10557484 | BEVACIZUMAB + CARBO + PACLITAXEL |
| 10004986 | 10003116 | 1.77 | 61.3 | null | 2017-05-23 | 2017-05-23 | IBRUTINIB | N | N | 10557484 | CETUXIMAB |
| 10004987 | 10003117 | 1.62 | 84.3 | null | 2018-09-17 | 2018-10-18 | CYTARABINE + IDARUBICIN + METHOTREXATE + RITUXIMAB | N | Y | 10558065 | CYCLOPHOSPHAMIDE + DOCETAXEL |
| 10004988 | 10003118 | 1.51 | 70.2 | Curative (C) | 2018-06-11 | 2018-06-20 | Cyclophosphamide + Docetaxel | N | N | 10558076 | TRASTUZUMAB |
| 10004989 | 10003118 | 1.65 | null | Palliative (P) | 2015-10-20 | 2015-10-20 | Cisplatin +Fluorouracil (3 wk) | N | N | 10558076 | TEMOZOLOMIDE |
| 10004990 | 10003119 | 1.85 | null | Palliative (P) | 2018-12-23 | 2018-12-23 | GEMCITABINE + OXALIPLATIN + RITUXIMAB | N | null | 10558185 | CARBO + FLUOROURACIL |
| 10004991 | 10003120 | 1.84 | 83.4 | Adjuvant (A) | 2017-09-25 | 2017-10-06 | ECarboX | 02 | N | 10558244 | MITOMYCIN INTRAVESICULAR |
| 10004992 | 10003120 | 1.7 | null | null | 2016-11-19 | 2016-12-03 | Capecitabine (21days) + Carboplatin | 2 | N | 10558244 | SORAFENIB |
| 10004993 | 10003121 | 1.67 | null | Curative (C) | 2017-05-24 | 2017-06-07 | PACE-BOM | 02 | N | 10558312 | CMV |
| 10004994 | 10003122 | null | 103.8 | Palliative (P) | 2019-05-29 | 2019-06-02 | Cetuximab + FLUOROURACIL + FOLINIC ACID + OXALIPLATIN | null | N | 10558463 | IRINOTECAN + MDG + PANITUMUMAB |
| 10004995 | 10003123 | 1.72 | 77.2 | Adjuvant (A) | 2016-07-17 | 2016-08-04 | CARBOPLATIN + FLUOROURACIL | 1 | N | 10558490 | PMITCEBO-R |
| 10004996 | 10003124 | 1.6 | null | Palliative (P) | 2018-09-23 | 2018-09-30 | AML16 Low Dose Cytarabine | 02 | N | 10558553 | TRASTUZUMAB |
| 10004997 | 10003125 | 1.55 | 51 | Neo-adjuvant (N) | 2015-08-11 | 2015-09-08 | BEVACIZUMAB + CARBO + PACLITAXEL | 02 | N | 10558568 | CETUXIMAB + IRINOTECAN + MDG |
| 10004998 | 10003125 | 1.78 | 60.7 | Curative (C) | 2018-07-31 | 2018-08-02 | Cisplatin + Docetaxel +Fluorouracil | null | null | 10558568 | MPV |
| 10004999 | 10003126 | null | null | Neo-adjuvant (N) | 2018-12-18 | 2019-01-02 | GEFITINIB | N | N | 10558747 | CARBO + FLUOROURACIL |
| 10005000 | 10003126 | 1.76 | 91.6 | Curative (C) | 2017-08-22 | 2017-08-24 | CISPLATIN + FLUOROURACIL + RT | N | N | 10558747 | RCEOP |
| 10005001 | 10003127 | 1.9 | 95.8 | Palliative (P) | null | 2015-08-23 | Gemcitabine+Paclitaxel (Neo-tAnGo) | Y | null | 10558782 | CAPECITABINE + MITOMYCIN + RT |
| 10005002 | 10006772 | 1.78 | 67 | null | 2018-06-10 | 2018-06-13 | Cytarabine low (10to20mg/m2) IV/SC | N | N | 10558965 | CAPECITABINE + EPIRUBICIN + OXALIPLATIN |
| 10005003 | 10006772 | 1.8 | 71 | Adjuvant (A) | 2017-12-21 | 2017-12-31 | CAPECITABINE + EPIRUBICIN + OXALIPLATIN | 2 | N | 10558965 | CAPECITABINE + MITOMYCIN |
| 10005004 | 10006772 | 0 | 73.6 | Unknown (U) | 2014-06-24 | 2014-06-25 | DOCETAXEL + FLUOROURACIL + OXALIPLATIN | 02 | N | 10558965 | BRENTUXIMAB |
| 10005005 | 10006772 | 1.85 | 0 | Curative (C) | 2017-12-13 | 2017-12-25 | Gefitinib: 1 to 2 & 4 onwards | Y | N | 10558965 | CYCLOPHOSPHAMIDE + RITUXIMAB |
| 10005006 | 10003128 | 1.72 | 94.6 | Palliative (P) | 2017-03-21 | 2017-03-24 | CYCLOPHOSPHAMIDE + ETOPOSIDE + RITUXIMAB | N | N | 10559257 | BENDAMUSTINE |